超短效β受体阻滞剂对初始复苏后持续心动过速的脓毒症患者死亡率的影响:随机对照试验的系统评价与Meta分析
本系统评价与Meta分析检索了MEDLINE、Cochrane CENTRAL和Embase,纳入比较艾司洛尔或兰地洛尔与安慰剂/无干预的随机对照试验,最终纳入7项RCT共613例患者,其中6项RCT共572例报告了28天死亡率。结果显示,在初始复苏后仍持续心动过速的脓毒症及脓毒性休克患者中,使用艾司洛尔或兰地洛尔与28天死亡率显著降低相关(RR 0.68,95%CI 0.54-0.85,P<.001),异质性不重要(I²=31%),绝对风险降低18.2%,需治疗人数5.5。作者结论认为该治疗与28天死亡率显著降低相关。
要点
- 在初始复苏后仍持续心动过速的脓毒症及脓毒性休克成人患者中,艾司洛尔或兰地洛尔与28天死亡率显著降低相关(RR 0.68,95%CI 0.54-0.85,P<.001)。
- 6项RCT共572例报告28天死亡率,绝对风险降低18.2%,需治疗人数5.5。
- 异质性不重要(I²=31%)。
- 纳入标准为年龄≥18岁的脓毒症及脓毒性休克患者,干预为艾司洛尔或兰地洛尔,对照为安慰剂或无干预。
适用人群与场景
- 年龄≥18岁的脓毒症及脓毒性休克患者,且初始复苏后仍持续心动过速。
研究设计与关键结果
- 系统评价与Meta分析纳入7项RCT,合并样本量613例;其中6项RCT共572例报告了28天死亡率。
- 在脓毒症及脓毒性休克患者中,使用艾司洛尔或兰地洛尔与28天死亡率显著降低相关(RR 0.68,95%CI 0.54-0.85,P<.001)。
- 异质性不重要(I²=31%)。
- 绝对风险降低为18.2%,预防一例死亡需治疗人数为5.5。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
对床旁实践的改变
- 作者结论认为,在初始复苏后仍持续心动过速的脓毒症患者中使用艾司洛尔或兰地洛尔与28天死亡率显著降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Historically, β-blockers have been considered to be relatively contraindicated for septic shock because they may cause cardiac suppression. On the other hand, there is an increasing interest in the use of β-blockers for treating patients with sepsis with persistent tachycardia despite initial resuscitation.
RESEARCH QUESTION: Do ultrashort-acting β-blockers such as esmolol and landiolol improve mortality in patients with sepsis with persistent tachycardia despite initial resuscitation?
STUDY DESIGN AND METHODS: This was a systematic review and meta-analysis. We searched MEDLINE, Cochrane Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) that compared the mortality of patients with sepsis and septic shock treated with esmolol or landiolol. We updated our search on April 20, 2020. Two independent reviewers assessed whether titles and abstracts met the following eligibility criteria: (1) RCT, (2) patients with sepsis and septic shock ≥ 18 years of age, and (3) treatment with either esmolol/landiolol or placebo/no interventions. Two authors independently extracted selected patient and study characteristics and outcomes. The results of all analyses are presented using random effect models.
RESULTS: Seven RCTs with a pooled sample size of 613 patients were included. Of these, six RCTs with 572 patients reported 28-day mortality. Esmolol or landiolol use in patients with sepsis and septic shock was significantly associated with lower 28-day mortality (risk ratio, 0.68; 95% CI, 0.54-0.85; P < .001). Unimportant heterogeneity was observed (I2 = 31%). The absolute risk reduction and number of patients to be treated to prevent one death were 18.2% and 5.5, respectively.
INTERPRETATION: The use of ultrashort-acting β-blockers such as esmolol and landiolol in patients with sepsis with persistent tachycardia despite initial resuscitation was associated with significantly lower 28-day mortality.
TRIAL REGISTRY: UMIN Clinical Trials Registry; No.: UMIN000040174; URL: https://www.umin.ac.jp/ctr/index.htm.
参考来源
- Hasegawa D, Sato R, Prasitlumkum N, et al. Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chest. 2021. PMID: 33434497. doi:10.1016/j.chest.2021.01.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。